Elevated Cystatin C Levels Are Associated with Cognitive Impairment and Progression of Parkinson Disease
Authors:
- 1 September 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 29 (3) , 144-149
Abstract
Objective: We investigated the relationship between serum cystatin C (CysC) levels and cognitive dysfunction and disease progression in patients with Parkinson disease. Background: Previous studies have reported altered CysC levels in neurodegenerative disorders, but only a few studies have explored the role of CysC and its relationship to cognitive dysfunction in Parkinson disease. Methods: We measured serum levels of CysC, creatinine, urea, and uric acid in 142 patients with Parkinson disease and 146 healthy controls. We assessed disease progression using the Hoehn and Yahr scale, and cognitive function using the Montreal Cognitive Assessment (Beijing version). Results: The patients with Parkinson disease had significantly higher CysC levels than the controls (Pr=0.494, Pr=0.150, P=0.011), and serum creatinine level (r=0.377, P0.05). CysC level was a significant independent predictor of Parkinson disease (odds ratio=23.143, 95% confidence interval: 5.485-97.648, Pr=0.098, Pr=−0.381, P=0.003). Conclusions: Serum CysC levels can predict disease severity and cognitive dysfunction in patients with Parkinson disease. The exact role of CysC remains to be determined.Keywords
This publication has 27 references indexed in Scilit:
- Neurocognitive impairment in Chinese patients with obstructive sleep apnoea hypopnoea syndromeRespirology, 2011
- The Combination of Homocysteine and C-Reactive Protein Predicts the Outcomes of Chinese Patients with Parkinson's Disease and Vascular ParkinsonismPLOS ONE, 2011
- Cystatin C Rescues Degenerating Neurons in a Cystatin B-Knockout Mouse Model of Progressive Myoclonus EpilepsyThe American Journal of Pathology, 2010
- Quantitation of non‐motor symptoms in Parkinson’s diseaseEuropean Journal of Neurology, 2008
- Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an EyewitnessNeurodegenerative Diseases, 2008
- Involvement of cystatin C in pathophysiology of CNS diseasesFrontiers in Bioscience-Landmark, 2008
- Genotype and Plasma Concentration of Cystatin C in Patients with Late-Onset Alzheimer DiseaseDementia and Geriatric Cognitive Disorders, 2007
- Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancyJournal of Bone and Mineral Research, 1992
- Cystatin C secretion by rat glomerular mesangial cells: Autocrine loop for in vitro growth-promoting activityBiochemical and Biophysical Research Communications, 1992
- ParkinsonismNeurology, 1967